Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | TDO2 | P48775 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | CASR | P41180 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL781357 | 1.00 | IDO1 (0.48) | IDO1TDO2AOC3ACHEHDAC4 | |
| SCHEMBL146546 | 1.00 | IDO1 (0.48) | IDO1TDO2AOC3ACHEHDAC4 | |
| SCHEMBL29876183 | 1.00 | IDO1 (0.48) | IDO1TDO2AOC3ACHEHDAC4 | |
| Hydrochloric Acid SCHEMBL780403 | 0.98 | IDO1 (0.52) | IDO1TDO2AOC3ACHEHDAC4 | |
| Bromide SCHEMBL28591637 | 0.98 | IDO1 (0.47) | IDO1TDO2AOC3ACHEHDAC4 | |
| Hydrochloric Acid SCHEMBL1239204 | 0.98 | IDO1 (0.52) | IDO1TDO2AOC3ACHEHDAC4 | |
| Iodide SCHEMBL29040444 | 0.98 | IDO1 (0.47) | IDO1TDO2AOC3ACHEHDAC4 | |
| Hydrochloric Acid SCHEMBL507110 | 0.98 | IDO1 (0.52) | IDO1TDO2AOC3ACHEHDAC4 | |
| SCHEMBL31020152 | 0.85 | IDO1 (0.44) | IDO1TDO2AOC3ACHEHDAC4 | |
| SCHEMBL659099 | 0.83 | ADRB2 (0.46) | SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114317475-B | Transaminase and application thereof in preparation of optically pure chiral amine | 上海合全药物研发有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-119899184-A | Beta-carboline compound, preparation method thereof and application thereof in resisting Alzheimer disease | 中国人民解放军北部战区总医院 | 2025-04-29 | — | — | CN | claimed |
| CN-118184650-A | 6- (1H-pyrrolo [2,3-b ] pyridin-3-yl) quinazoline-4-amine derivative, and preparation method and application thereof | 中国人民解放军北部战区总医院 | 2024-06-14 | — | — | CN | claimed |
| CN-114317475-A | Transaminase and application thereof in preparation of optically pure chiral amine | 上海合全药物研发有限公司 | 2022-04-12 | — | — | CN | claimed |
| EP-2121617-B1 | CB1 RECEPTOR MODULATORS | 7TM PHARMA AS (DK) | 2014-01-22 | — | — | EP | claimed |
| US-20100010061-A1 | CB1 RECEPTOR MODULATORS | 7TM PHARMA A/S (DK) | 2010-01-14 | — | — | US | claimed |
| EP-2121617-A1 | CB1 RECEPTOR MODULATORS | 7TM Pharma A/S (DK) | 2009-11-25 | — | — | EP | claimed |
| WO-2008075012-A1 | CB1 RECEPTOR MODULATORS | 7TM PHARMA A/S (DK) | 2008-06-26 | — | — | WO | claimed |
| US-12606541-B2 | PPARg modulators and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| US-20250326756-A1 | METHOD FOR PRODUCING 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | NUVATION BIO INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250282728-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | CEREVANCE INC (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4612131-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12338262-B2 | Modulators of TNF-alpha activity | FORWARD THERAPEUTICS, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| CN-114317475-B | Transaminase and application thereof in preparation of optically pure chiral amine | 上海合全药物研发有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-7186865-B2 | Reacting optically active secondary amine with alkylation agent in presence of a base, thereby converting the secondary amine into an optically active tertiary amine and subjecting the tertiary amine to hydrogenolysis, producing the N-monoalkyl derivative; intermediates for drugs, agriculture | CENTRAL GLASS COMPANY, LIMITED (JP) | 2007-03-06 | — | — | US | disclosed |
| US-20060058308-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-03-16 | — | — | US | disclosed |
| US-20040235961-A1 | Optically active 1-(fluoro-, trifluoromethyl-or trifluoromethoxy-substituted phenyl) alkylamine n-monoalkyl derivatives and process for producing same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
| US-6329405-B1 | AS ILEAL BILE ACID TRANSPORTER INHIBITOR, FOR THERAPY OF HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 2001-12-11 | — | — | US | disclosed |
| CN-1287117-A | Cyclobutene derivatives, preparation method and therapeutic use thereof | SANKYO CO (JP) | 2001-03-14 | — | — | CN | disclosed |
| EP-1070703-A1 | Cyclobutene derivatives | Sankyo Company Limited (JP) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058308-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | IDO1 467/4885TDO2 328/4885AOC3 2597/4885 |
| US-20040235961-A1 | Optically active 1-(fluoro-, trifluoromethyl-or trifluoromethoxy-substituted phenyl) alkylamine n-monoalkyl derivatives and process for producing same | NAT1, PNMT, AFF1 | IDO1 362/4885TDO2 262/4885AOC3 111/4885 |
| US-20250326756-A1 | METHOD FOR PRODUCING 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | NISCH, CYP4B1, CYP2W1 | IDO1 83/4885TDO2 296/4885AOC3 397/4885 |
| US-20100010061-A1 | CB1 RECEPTOR MODULATORS | CNR1, CNR2, GPR6 | IDO1 3678/4885TDO2 2120/4885AOC3 1026/4885 |
| US-12606541-B2 | PPARg modulators and methods of use | PPARG, PPARA, PPARD | IDO1 2570/4885TDO2 2789/4885AOC3 2901/4885 |
| US-20250282728-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | GPR55, GPR68, GPR65 | IDO1 2010/4885TDO2 2352/4885AOC3 2216/4885 |
| US-12338262-B2 | Modulators of TNF-alpha activity | TNF, TNFRSF1A, NFKBIA | IDO1 1754/4885TDO2 4471/4885AOC3 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.